LRMR PE Ratio & Valuation, Is LRMR Overvalued
Larimar Therapeutics Inc (LRMR) is currently in the "Fair zone" according to its forward PS ratio of 7.95, which is compared to a five-year average of -3.46. While its current Price-to-Book (P/B) ratio of 6.37 is significantly higher than its 3-year and 5-year averages, its Forward Free Cash Flow (FCF) yield is -22.77%. The article also notes that LRMR's P/S ratio of 7.95 is significantly above the industry average, suggesting that its premium based on growth may be unsustainable.
Q1 Earnings Estimate for LRMR Issued By Lifesci Capital
Lifesci Capital has issued Q1 2026 EPS estimates for Larimar Therapeutics (NASDAQ:LRMR) at ($0.66) per share, maintaining a "Strong-Buy" rating. The consensus rating for LRMR is a "Buy" with an average price target of $16.50. The article also highlights recent insider buying activity and institutional investor holdings.
LRMR SEC Filings - Larimar Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Larimar Therapeutics, Inc. (LRMR) SEC filings, including 10-K, 10-Q, and 8-K reports, detailing the company's clinical progress, financial condition, and key events. Larimar is a clinical-stage biotechnology company focused on rare diseases, with its lead compound, nomlabofusp, in development for Friedreich's ataxia. The platform also offers AI-powered summaries, impact scoring, and sentiment analysis for these regulatory documents, alongside real-time updates and insider transaction data.
Wedbush raises its price target on Larimar Therapeutics (LRMR) to $13
Wedbush has increased its price target for Larimar Therapeutics (LRMR) to $13. This indicates a positive outlook from the analyst firm regarding the company's future stock performance.
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13
Wedbush has increased its price target for Larimar Therapeutics (LRMR) to $13 from $12, maintaining an Outperform rating. This decision follows Larimar's Q4 update, which met expectations as the company prepares to submit its nomlabofusp regulatory application in June 2026. Larimar reported Q4 EPS of (73c) and a strong cash position, supporting its operations into Q2 2027.
Larimar Therapeutics (NASDAQ:LRMR) Stock Rating Upgraded by Truist Financial
Truist Financial upgraded Larimar Therapeutics (NASDAQ:LRMR) to a "strong-buy" rating, contributing to an overall analyst consensus of "Buy" with a $16.50 price target. This comes after Director James E. Flynn made a significant insider purchase of 5,000,000 shares for $25,000,000, increasing his stake to over 10 million shares. Despite recent earnings missing expectations, the company is advancing its lead product candidate, CTI-1601, for Friedreich's ataxia in Phase 2 clinical trials.
Larimar Reports Results, Advances Nomlabofusp Toward FDA Filing
Larimar Therapeutics, Inc. reported its Q4 and full-year 2025 financial results and provided updates on its lead candidate, nomlabofusp, for Friedreich’s ataxia. The company plans an FDA filing for accelerated approval in June 2026 and expects its cash runway to extend into Q2 2027 following a recent public offering. The FDA has granted Breakthrough Therapy Designation for nomlabofusp and agreed on key aspects for the planned Biologics License Application and Phase 3 study.
FDA grants Breakthrough status to rare disease drug as June filing nears
Larimar Therapeutics (NASDAQ: LRMR) announced that the FDA granted Breakthrough Therapy Designation to nomlabofusp for Friedreich’s ataxia, with a Biologics License Application (BLA) submission seeking accelerated approval planned for June 2026. The company also reported Q4 and full-year 2025 financial results, including a net loss of $165.7 million for the year, and strengthened its balance sheet with a $115 million public offering, extending its cash runway into Q2 2027. Investors are advised to watch for upcoming open-label data and Phase 3 initiation as key indicators of execution risk.
Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday
Larimar Therapeutics (LRMR) is set to announce its Q4 2025 earnings before market open on Monday, March 30th, with analysts expecting a loss of ($0.41) per share. Despite missing previous estimates and projected negative EPS for the coming fiscal years, the stock maintains a consensus "Buy" rating and a mean price target of $16.43. Noteworthy insider activity includes a significant purchase by Director James E. Flynn, increasing his stake by 88.9%.
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade
Larimar Therapeutics' (NASDAQ:LRMR) stock price rose by 8.2% after Wedbush increased its price target to $13.00. The company also saw significant insider buying, with Director James E. Flynn purchasing 5,000,000 shares worth $25 million, and strong institutional accumulation of its stock. Analysts currently hold a consensus "Buy" rating for LRMR with an average price target of $16.43.
Wedbush Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $13.00
Wedbush has increased its price target for Larimar Therapeutics (NASDAQ:LRMR) to $13.00 from $12.00, maintaining an "outperform" rating and implying a potential upside of 190.83%. This adjustment aligns with a general "Buy" consensus from other analysts, with an average price target of $16.43. The report also highlights a significant insider purchase by Director James E. Flynn, who acquired 5,000,000 shares for $25,000,000, substantially increasing his stake in the company.
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Larimar Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant progress for its lead compound, nomlabofusp, in treating Friedreich's ataxia (FA). The company received Breakthrough Therapy Designation from the FDA and is on track for a Biologics License Application (BLA) submission in June 2026, targeting an accelerated approval and a mid-2027 U.S. launch. Larimar also completed a successful $115 million public offering, extending its cash runway into the second quarter of 2027.
Larimar Therapeutics, Inc. has established a clear regulatory approval and commercialization timeline for its core candidate product.
Larimar Therapeutics, Inc. has outlined a timeline for its core candidate product, intending to submit a Biologics License Application (BLA) to the FDA in June 2026. The company anticipates an official launch in the U.S. market in the first half of 2027, assuming a successful approval process. This plan provides a clear commercialization path for their therapeutic offering.
Larimar Therapeutics, Inc. has established a clear regulatory approval and commercialization timeline for its core candidate product.
Larimar Therapeutics, Inc. has set a clear timeline for its core product, planning to submit a Biologics License Application (BLA) to the FDA in June 2026. If approved without issues, the company expects to launch the therapy in the U.S. market in the first half of 2027.
Larimar (NASDAQ: LRMR) secures FDA Breakthrough status and funds runway to 2027
Larimar Therapeutics (NASDAQ: LRMR) announced a wider net loss of $165.7 million in 2025 but achieved FDA Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia. The company has secured $244.5 million in pro forma liquidity, extending its cash runway into Q2 2027, and plans a Biologics License Application (BLA) submission for nomlabofusp in June 2026, targeting a U.S. launch in early 2027 if approved. Despite increased R&D expenses driven by manufacturing and clinical costs, regulatory alignment with the FDA on using frataxin as a surrogate endpoint underpins a clear development path for its lead asset.
Larimar Therapeutics Q4 net loss widens on higher R&D costs
Larimar Therapeutics reported a wider net loss in the fourth quarter due to increased research and development costs. The article, a brief report from Reuters via Refinitiv, indicates that the Q4 earnings were negatively impacted by these higher expenses.
Larimar: Q4 Earnings Snapshot
Larimar Therapeutics, Inc. (LRMR) reported a fourth-quarter loss of $62.5 million, or 73 cents per share, which missed Wall Street expectations of 44 cents per share. For the entire year, the company had a loss of $165.7 million, or $2.27 per share. This financial data was generated by Automated Insights using information from Zacks Investment Research.
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Larimar Therapeutics reported its Q4 and full-year 2025 financial results, highlighting significant progress toward the accelerated approval of nomlabofusp for Friedreich's ataxia. Key developments include Breakthrough Therapy Designation from the FDA, alignment with the FDA on BLA content including the use of FXN as a novel surrogate endpoint, and a strengthened balance sheet with cash runway into Q2 2027 following a $115 million public offering. The company expects to submit its BLA in June 2026 and initiate a global Phase 3 confirmatory study in Q2 2026, with a targeted U.S. launch in the first half of 2027 if approved.
Larimar: Q4 Earnings Snapshot
Larimar Therapeutics, Inc. (LRMR) reported a fourth-quarter loss of $62.5 million, or 73 cents per share, missing Wall Street expectations of 44 cents per share. For the entire year, the company's loss totaled $165.7 million, or $2.27 per share. This financial update was generated using data from Zacks Investment Research.
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Sees Significant Decrease in Short Interest
Larimar Therapeutics (NASDAQ:LRMR) experienced a significant 14.3% decrease in short interest in February, with total shares sold short falling to 7,692,689 shares. This represents a days-to-cover ratio of 0.6 days and approximately 7.8% of the stock's float. The article also highlights a substantial insider purchase by Director James E. Flynn and a generally bullish outlook from analysts, who have an average "Buy" rating and a target price of $16.29.
Mangrove Partners IM LLC Sells 327,997 Shares of Larimar Therapeutics, Inc. $LRMR
Mangrove Partners IM LLC significantly reduced its stake in Larimar Therapeutics, Inc. by selling 327,997 shares, lowering its total holding to 442,236 shares. This contrasts with a major insider purchase by Director James E. Flynn, who bought 5,000,000 shares for $25 million, increasing his ownership to 10,622,957 shares. The company maintains a "Buy" rating among analysts with an average target price of $16.29, despite the institutional sell-off.
Larimar Advances Nomlabofusp Toward 2026 BLA Submission
Larimar Therapeutics provided an update on its nomlabofusp program for Friedreich's ataxia, aiming for a June 2026 BLA submission. The FDA has granted Breakthrough Therapy Designation, and the company has identified skin FXN levels as a potential surrogate endpoint and Upright Stability Score as a primary endpoint for a global Phase 3 study. Larimar anticipates a cash runway into Q2 2027 and has received a "Buy" rating from analysts with a $12.00 price target.
Larimar Therapeutics (LRMR) advances nomlabofusp toward 2026 BLA and Phase 3
Larimar Therapeutics provided an update on its nomlabofusp program for Friedreich's ataxia, outlining a plan for a Biologics License Application (BLA) seeking accelerated approval by June 2026. The drug has received FDA Breakthrough Therapy and other expedited designations, with open-label study data showing sustained increases in frataxin levels and numerical improvements in clinical outcomes. While the program shows positive regulatory momentum and strong funding, safety concerns include anaphylaxis events in some participants, which resolved with standard treatment.
Larimar Advances Nomlabofusp Toward 2026 BLA Submission
Larimar Therapeutics has provided an update on its nomlabofusp program for Friedreich’s ataxia, announcing Breakthrough Therapy Designation from the FDA and other expedited development designations. The company aims for a June 2026 BLA submission, supported by positive open-label data and a projected cash runway into mid-2027. LRMR currently holds a "Buy" rating from analysts with a $12.00 price target.
Larimar Therapeutics posts updated corporate deck outlining nomlabofusp BLA plan, Q2 2026 topline and cash runway
Larimar Therapeutics has released an updated corporate deck detailing its plans for nomlabofusp, including a targeted BLA submission in June 2026 for accelerated approval and expected topline open-label data in Q2 2026. The company also announced that previous discussions with the FDA align on key regulatory aspects for the drug. Furthermore, Larimar Therapeutics reported a pro forma cash and investments of $244.5 million as of December 31, 2025, providing a projected cash runway into Q2 2027.
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Analysts
Larimar Therapeutics, Inc. (NASDAQ:LRMR) has received a "Buy" consensus recommendation from ten brokerages, with an average one-year price target of $16.29. Insider activity shows Director James E. Flynn recently purchased 5 million shares for $25 million, significantly increasing his holdings. The company's stock opened at $5.22, with institutional investors holding a substantial 91.92% of its shares.
Blue Owl Capital Holdings LP Has $18.91 Million Stock Holdings in Larimar Therapeutics, Inc. $LRMR
Blue Owl Capital Holdings LP significantly increased its stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 18.8% in the third quarter, bringing its total holdings to 5,853,040 shares valued at $18.91 million. This makes Larimar Therapeutics Blue Owl's fourth-largest holding. Additionally, Director James E. Flynn recently purchased 5 million shares, substantially increasing his ownership and reflecting insider confidence. The company currently has an average "Buy" rating from analysts with an average target price of $16.29.
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
Larimar Therapeutics (LRMR) shares have surged 55% in the past month following significant regulatory updates for its lead drug, nomlabofusp, which is designed to treat Friedreich’s ataxia (FA). The FDA granted breakthrough therapy designation to nomlabofusp and indicated a willingness to consider skin frataxin (FXN) levels as a surrogate endpoint for accelerated approval. Larimar aims to file for regulatory approval in June 2026, with a potential commercial launch in the first half of 2027.
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Larimar Therapeutics announced its participation in two upcoming investor conferences in Miami Beach, FL. The company's management will present and hold one-on-one investor meetings at the Leerink Partners Global Healthcare Conference on March 10, 2026, and The Citizens Life Sciences Conference on March 11, 2026. Webcast links for both presentations are provided, and replays will be available on Larimar’s website.
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Larimar Therapeutics, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences in March 2026: the Leerink Partners Global Healthcare Conference and The Citizens Life Sciences Conference. Management will provide presentations and engage in one-on-one meetings. The company is focused on developing treatments for rare diseases, with its lead compound, nomlabofusp, targeting Friedreich's ataxia.
Biotech Larimar heads to Miami for back-to-back investor meetings in March
Larimar Therapeutics (NASDAQ: LRMR) announced its management will participate in two investor conferences in Miami Beach, FL, in March 2026. The company will present and hold 1x1 investor meetings at the Leerink Partners Global Healthcare Conference on March 10 and The Citizens Life Sciences Conference on March 11. Replays of the presentations will be available for 30 days on Larimar’s website.
FDA Grants Breakthrough Status to Larimar’s Nomlabofusp
The FDA has granted Breakthrough Therapy Designation to Larimar Therapeutics' nomlabofusp for Friedreich’s ataxia, based on promising clinical data showing increased frataxin protein levels and improved clinical measures. This designation supports Larimar's plan to submit a Biologics License Application in June 2026, targeting accelerated approval and a U.S. launch in early 2027. Friedreich's ataxia is a rare, inherited neurological disease affecting approximately 5,000 people in the United States.
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026
Wedbush has maintained an Outperform rating for Larimar Therapeutics, Inc. (LRMR) and increased its price target to $12 following updated model inputs and program milestones. This signals continued confidence in the company, which saw a modest 1.85% stock increase on the news. Given LRMR's limited coverage, this analyst update is particularly significant for investors, providing a clear upside benchmark.
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Larimar Therapeutics, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences in Miami Beach, FL. Management will present and engage in 1x1 meetings at the Leerink Partners Global Healthcare Conference and The Citizens Life Sciences Conference in March 2026. The company is focused on developing treatments for complex rare diseases, with nomlabofusp as its lead compound for Friedreich's ataxia.
Larimar Therapeutics: Deerfield entities buy $25m in stock
Deerfield Management and its affiliated entities, including director James E. Flynn, recently purchased 5,000,000 shares of Larimar Therapeutics (NASDAQ:LRMR) common stock for $25 million at $5.00 per share. This significant investment follows a public offering of $100 million and the FDA's Breakthrough Therapy Designation for Larimar's drug nomlabofusp, indicating positive financial and regulatory developments for the company. Larimar Therapeutics also holds more cash than debt, according to InvestingPro analysis.
James Flynn Acquires 5,000,000 Shares of Larimar Therapeutics (NASDAQ:LRMR) Stock
Director James Flynn recently acquired 5,000,000 shares of Larimar Therapeutics (NASDAQ:LRMR) for $25 million, increasing his stake by 88.92% to over 10.6 million shares. The clinical-stage biotech company, developing CTI-1601 for Friedreich's ataxia, currently trades near $5.23, with analysts generally maintaining positive ratings and an average price target of $16.14. Institutional investors have also been adjusting their holdings in LRMR.
Larimar Therapeutics (NASDAQ:LRMR) Price Target Raised to $12.00
Wedbush has increased its price target for Larimar Therapeutics (NASDAQ:LRMR) to $12.00 from $11.00, maintaining an "outperform" rating, which suggests a 124.93% upside. Citigroup also raised its target to $14.00, contributing to a Street consensus "Buy" rating and an average price target of $16.29. Additionally, Director James E. Flynn significantly increased his stake in the company by purchasing 5 million shares for $25 million.
Wedbush raises Larimar Therapeutics stock price target to $12
Wedbush has increased its price target for Larimar Therapeutics (NASDAQ:LRMR) to $12 from $11, maintaining an Outperform rating. This follows Larimar's successful $100 million offering and Breakthrough Therapy designation for its drug nomlabofusp in Friedreich's ataxia, causing a 42% surge in stock price. The company shows strong financial health and aims for a BLA submission by June 2026, with a potential approval by February 2027 and commercial launch in Q2 2027.
LRMR News & Events
This page provides news and event updates for LRMR stock, Larimar Therapeutics. Recent news highlights include Larimar Therapeutics pricing an upsized public offering of 20 million shares, following an FDA Breakthrough Designation for its drug Nomlabofusp. Notable events include the increase in deal size for the offering to $100M, managed by JPMorgan and Guggenheim.
Larimar Therapeutics (LRMR) Is Up 85.9% After Breakthrough Status For Nomlabofusp In Friedreich’s Ataxia
Larimar Therapeutics (LRMR) saw an 85.9% increase in its stock after the FDA granted Breakthrough Therapy Designation to nomlabofusp for treating Friedreich’s ataxia. This development, coupled with FDA alignment on using skin frataxin as a surrogate endpoint and a recent $100 million equity raise, significantly sharpens the near-term catalysts for the company's accelerated Biologics License Application filing. While the stock has moved sharply, investors are now focusing on regulatory outcomes, execution of the global Phase 3, and the impact of share dilution on long-term returns.
LRMR Stock Price, Forecast & Analysis | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR)
This article provides an analysis of LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) stock, including its current price of $5.31, recent performance, and key statistics like a market cap of $441.21 million. It highlights ChartMill's technical rating of 9/10 and a fundamental rating of 2/10, along with analyst consensus for a price target of $15.50. The company profile details LRMR as a clinical-stage biopharmaceutical company focused on treatments for mitochondrial disorders and Friedreich's ataxia.
Larimar Therapeutics Prices $5.00 Public Offering, Nets ~$107.6 Million as Option Is Exercised
Larimar Therapeutics announced a public offering of 20,000,000 shares at $5.00 per share, with underwriters (J.P. Morgan Securities and Guggenheim Securities) fully exercising an option for 3,000,000 additional shares. This offering is expected to net the company approximately $107.6 million, with all shares being sold by Larimar Therapeutics to raise capital for general corporate purposes. The offering is anticipated to close on February 27, 2026.
Larimar Therapeutics Announces Upsized Public Equity Offering
Larimar Therapeutics announced an upsized public equity offering of 23 million shares, generating approximately $107.6 million in net proceeds. The offering, underwritten by J.P. Morgan Securities LLC and Guggenheim Securities, LLC, is expected to close on February 27, 2026. This capital raise will support the company's ongoing operations and strategic initiatives, despite its weak financial performance and bearish technical signals.
Larimar Therapeutics prices $100M stock offering at $5 per share
Larimar Therapeutics has priced an underwritten public offering of 20 million shares of common stock at $5.00 per share, aiming to raise $100 million in gross proceeds. The clinical-stage biotechnology company plans to use the net proceeds to advance its drug nomlabofusp, a potential treatment for Friedreich’s ataxia, and for general corporate purposes. This offering follows recent positive developments, including the FDA granting Breakthrough Therapy Designation for nomlabofusp and Leerink Partners initiating coverage with an Outperform rating.
Larimar Therapeutics, Inc. Prices Upsized Public Offering of 20 Million Shares at $5.00 Each
Larimar Therapeutics, Inc. has announced the pricing of an upsized public offering of 20 million shares of common stock at $5.00 per share, aiming to raise $100 million before expenses. The proceeds will fund the development of its lead compound, nomlabofusp, for Friedreich’s ataxia, and for general corporate purposes. The offering is expected to close around February 27, 2026, with an option for underwriters to purchase an additional 3 million shares.
Larimar Therapeutics, Inc. Prices Upsized Public Offering of 20 Million Shares at $5.00 Each
Larimar Therapeutics, Inc. has priced an upsized public offering of 20 million shares of common stock at $5.00 per share, aiming to raise $100 million before expenses. The proceeds will primarily fund the development of its lead compound, nomlabofusp, for Friedreich’s ataxia, and general corporate purposes. This offering includes a 30-day option for underwriters to purchase an additional 3 million shares and is expected to close around February 27, 2026.
Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp
Larimar Therapeutics (LRMR) received FDA Breakthrough Therapy Designation for nomlabofusp, its Friedreich's ataxia candidate, leading to significant stock price momentum. Despite ongoing losses and an "undervalued" price-to-book ratio of 2.3x compared to peers, the company faces clinical trial risks and continued unprofitability for the next three years. Investors are urged to consider both the potential upside from the FDA news and the inherent risks associated with a development-stage biotech.
Larimar Therapeutics launches $75M public stock offering
Larimar Therapeutics (NASDAQ:LRMR) has announced an underwritten public offering of $75 million in common stock and pre-funded warrants. The offering follows a 25% surge in shares over the past week and aims to fund the development of nomlabofusp and general corporate purposes. This capital raise is timely, given the company's cash burn rate, though InvestingPro data indicates it holds more cash than debt and the stock appears overvalued.
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
Larimar Therapeutics, a clinical-stage biotechnology company, announced the pricing of an upsized underwritten public offering of 20,000,000 shares of its common stock at $5.00 per share, aiming to raise $100 million in gross proceeds. The company plans to use these proceeds to fund the development of nomlabofusp, its lead compound for Friedreich’s ataxia, and for general corporate purposes. The offering is expected to close around February 27, 2026, with J.P. Morgan and Guggenheim Securities acting as joint bookrunning managers.
Rare-disease biotech Larimar seeks $75M to fund key drug
Larimar Therapeutics announced a proposed underwritten public offering to raise $75 million, with an option for underwriters to purchase an additional $11.25 million in securities. The proceeds are intended to fund the development of its lead drug, nomlabofusp, for Friedreich's ataxia, as well as for general working capital and research and development expenses. The announcement led to a significant positive market reaction, with Larimar's stock gaining over 61% and increased trading volume.
